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Why don’t fistulas mature?
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Fistula maturation requires a compliant and responsive
vasculature capable of dilating in response to the
increased velocity of blood flowing into the newly created
low-resistance circuit. Successful maturation to a high
volume flow circuit capable of sustaining hemodialysis
typically occurs within the first few weeks after creation.
Failure to achieve maturation within 4–8 weeks should
prompt a search for reversible etiologies; however, an
accepted definition of maturation, particularly for
patients not yet on dialysis remains elusive. The most
commonly identified etiology is neointimal hyperplasia
typically occurring in the juxta-anastomotic vein.
However, failed maturation has also been reported
secondary to impaired arterial and venous dilation and
accessory veins. The exact frequency of each of these
etiologies is unclear. Understanding the etiologies of
impaired fistula maturation will focus future studies of
targeted interventions to improve the rate of fistula
maturation and increase the number of dialysis
patients with a functioning autogenous fistula.
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An autogenous arteriovenous fistula formed by the direct
anastomosis of adjacent artery and vein is the optimal
vascular access for hemodialysis. Once it has matured into a
useable access, the autogenous fistula has the longest survival
rate with the fewest complications of any form of vascular
access.1 The problem is that many autogenous fistulas do not
mature into a usable hemodialysis access. In recent literature
between 20 and 50% of autogenous fistulas fail to mature.2
Maturation rates are lower for radiocephalic than for
brachiocephalic fistulas. Several other recent reviews covering
various aspects of arteriovenous fistula creation, complica-
tions, timing of use and the biology of access failure are also
available.3–5 The goal of this contribution is to focus on
factors that determine fistula maturation and offer insights as
to where we may look to improve.
DEFINITION OF FISTULA MATURATION
A fistula is mature when it can be routinely cannulated with
two needles and deliver a minimum blood flow (typically
350–450 ml/min) for the total duration of dialysis, usually
3–5 h for high efficiency hemodialysis. Typically a mature
forearm fistula will have a blood flow of 500–2000 ml/min
and an upper arm fistula 500–3000 ml/min.6 Currently,
there is no well-established criterion that defines fistula
maturation. New vascular access guidelines from the National
Kidney Foundation-Kidney Dialysis Outcomes Quality
Initiative will recommend criteria to define maturation, but
they have not yet been validated in a clinical trial. Most
current studies use clinical criteria to define maturation but
this requires that the access be cannulated for dialysis and there
is no agreement on when to assess maturation or how many
successful dialysis sessions are needed to establish that a fistula
has matured. For instance, Beathard et al.7 required that the
fistula be functional at 3 months or it was considered an early
failure. In the fistula study currently being conducted by the
Dialysis Access Consortium, investigators operationally de-
fined access suitability (or maturation) for those patients
already on dialysis as the ability to use the fistula by 4 months
after access creation. In addition, the fistula must be able to
deliver a minimum blood flow of 300 ml/min for at least eight
dialysis sessions during the ensuing 30 days.8 Patients who
started dialysis after this time point needed to meet these
criteria within the first month on dialysis. Clearly no
consensus exists, but a better understanding of the physiology
of fistula maturation and the pathogenesis of early failure will
help to promote a more uniform definition of maturation.
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PHYSIOLOGY OF FISTULA MATURATION
Creation of an arteriovenous fistula bypasses resistance
vessels in the distal extremity and establishes a parallel,
fixed, low-resistance return pathway to the heart. Volume
flow through the fistula increases as a result of the reduced
resistance. Loss of perfusion to other vascular beds is
prevented by a reflex increase in cardiac output that
compensates for the increased flow through the fistula and
maintains blood pressure. Adequate perfusion of the tissue in
the extremity distal to the fistula requires sufficient dilation
of the arterial system proximal to the fistula to compensate
for the shunting of blood through the fistula. In most
patients, flow through the artery proximal to the fistula does
not increase sufficiently to meet the demands of the fixed
shunt through the fistula.9,10 In this case, retrograde flow in
the artery distal to the fistula helps feed the low-resistance
shunt pathway but in the process steals blood flow from the
distal extremity. Stenosis or narrowing in the proximal artery
will exacerbate the distal steal.11,12 When severe, this can lead
to tissue ischemia and pain that may require fistula ligation
or a distal revascularization and interval ligation procedure to
restore distal tissue perfusion.3
Fistula maturation depends on obtaining sufficient flow
through the fistula to support hemodialysis and prevent
thrombosis. Fistula flow rate depends on the pressure
gradient and the total resistance in the fistula circuit
including the proximal artery, fistula anastomosis, and the
downstream vein. Although much attention has focused on
the downstream vein, it is often forgotten that arterial
blood flow must also increase substantially for successful
fistula maturation. Mean blood flow in the brachial artery at
rest is around 50 ml/min, whereas mean blood flow in the
radial artery at rest is typically less than 25 ml/min.13–16 With
exercise or reactive hyperemia brachial artery mean blood
flow can increase 3–5-fold.13,17 However, for a successful
fistula mean blood flow in the artery must increase by at least
10–20-fold (to at least 500 ml/min). In order to accommodate
this increase in blood flow, the artery must dilate. Based
on Pouseuille’s law, where blood flow (Q) is proportional to
the product of the pressure gradient (DP) and vessel radius
(r) to the fourth power divided by the viscosity (Z) of blood
(QpDP r4/Z), if blood flow is steady and the pressure-
gradient down the artery as well as the blood viscosity are
constant then the brachial artery lumen would need to dilate
by nearly 80% to achieve a 10-fold increase in flow rate
(100.25¼ 1.78). In most studies, the actual measured increase
in radial or brachial artery diameter after creation of an
arteriovenous fistula is only 40–50%.16,18–20 The difference
can be accounted for by several factors. First, arterial flow is
pulsatile rather than steady and the average pressure gradient
is not fixed but increases following fistula placement.15 Before
fistula creation, pulsatile flow in the brachial or radial artery
is antegrade for only part of each cardiac cycle and falls to
zero or below (i.e. retrograde flow) during diastole (Figure 1).
Following creation of the low-resistance fistula, flow in the
artery remains high and antegrade throughout the cardiac
cycle implying that the average arterial pressure gradient
following fistula creation has increased.15 Hence, mean flow
rate (the time-averaged area under the flow curve) for a given
artery diameter is much greater. Second, blood viscosity
decreases with increasing flow rate thus limiting the increase
in wall shear stress (WSS) (friction) for any given vessel
radius.20 Finally, as discussed above and shown in Figure 1,
retrograde flow from the distal artery occurs in about 75% of
forearm fistulas and accounts for an average of 25% of the
blood flow into the venous limb of the fistula.9 Together,
these factors limit the magnitude of the dilation in the
proximal artery that is required to achieve the necessary
10–20-fold increase in flow rate. Nonetheless, substantial
arterial dilation and remodeling is still required for successful
fistula maturation.
Changes in pressure and flow are the stimulus for vascular
dilation and remodeling after fistula formation. Pressure and
flow exert their effect by causing deformation and there-
by creating opposing stresses within the vessel wall.21 The
deformations of the vessel occur in three directions:
circumferential, radial, and longitudinal. These deformations
create both normal (i.e. tensile or compressive) stress and
shear (tangential) stress in each of the three directions. Thus,
there are a total of nine static mechanical factors (three static
deformations and six static stresses) that may influence
vascular dilation and remodeling. This is further complicated
by the fact that pressure and flow vary with time (i.e. are
pulsatile) and thus each of these nine factors also varies with
time. This makes it difficult to isolate and understand the
exact contribution of each mechanical factor to the process of
vascular remodeling. Most studies have focused on the role of
only three factors, (longitudinal) shear stress, circumferential
deformation, and circumferential (tensile) stress. However, a
study by Dobrin et al.21 looked at the effect of nine of the
most likely mechanical factors (three static deformations,
three static stresses, pulsatile deformation and pulsatile stress
each as an aggregate single factor, and longitudinal WSS)
on vascular remodeling in an interposition vein graft.21
They found that intimal thickening correlated with low WSS
and medial thickening correlated with circumferential
deformation. A similar detailed analysis of mechanical factors
influencing arterial or venous dilation and remodeling after
fistula formation has not been performed. However, the
study by Dobrin seems to validate the central importance of
longitudinal shear stress and circumferential deformation
and stress as the central mechanical factors influencing
vascular dilation and remodeling.
Based on experimental models and clinical studies, the
major stimulus for arterial vasodilation and remodeling after
fistula formation is the increase in blood flow velocity and
attendant increase in WSS.19,22,23 Shear stress is sensed by the
endothelium and loss of endothelial cells impairs arterial
dilation, vascular remodeling, and normalization of WSS
after fistula formation.24 The exact biophysical mechanism
whereby endothelial cells sense and transmit intracellular
information about shear stress is incompletely understood.25
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The increase in shear stress leads to release of nitric oxide and
other endothelium-dependent vasodilators that dilate the
artery and tend to restore shear stress back towards
baseline.23,26,27 Although substantial arterial dilation (24%)
occurs immediately upon fistula creation,16 further dilation is
required over the subsequent days and weeks to normalize
arterial shear stress.16,22 In contrast to earlier reports, a recent
study by Dammers et al.20 found that despite substantial
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Figure 1 | Overview of fistula maturation. The figure depicts the temporal pattern from top to bottom of successful (left) and unsuccessful
(right) fistula maturation in a radiocephalic fistula. The top of the figure shows the preoperative flow and pressure in the radial artery and
cephalic vein. The inset shows the volume flow in the radial artery through two cardiac cycles. Note that flow rate returns to zero during
diastole. The middle two figures depict the situation 1 day after fistula creation for a fistula that has dilated rapidly and is likely to mature (left)
or one that has not dilated sufficiently and is likely to fail (right). The middle graph inset shows that after creation of the low-resistance
circuit, volume flow rate remains high and significantly above zero throughout both systole and diastole. Thus, the mean volume flow rate is
much greater than predicted for the extent of arterial dilation by Pouseuille’s law. Note the turbulent flow at the arteriovenous anastomosis
creates resistance that drops venous pressure to about a third of arterial pressure. The three figures at the bottom depict the situation
at 4–8 weeks after fistula creation for a successful fistula (left) or two possible modes of early fistula failure – the development of a
juxta-anastomotic stenosis (middle) or impaired dilation (right). Between 20 and 50% of radiocephalic fistulas will fail to mature and
between 65 and 100% will have evidence of a stenosis.
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arterial dilation, the increase in shear stress did not normalize
even 1 year after fistula creation. This suggests that arterial
adaptation after fistula creation may be incomplete.
The mechanistic steps leading to arterial dilation and
remodeling after fistula formation have not been completely
elucidated. However, the early rapid phase of arterial dilation
is likely mediated by smooth muscle relaxation in response to
endothelial release of nitric oxide and other vasodilators.23,26
By itself, this early vasorelaxation is not sufficient to
normalize arterial shear stress.18,22 In experimental studies
of fistula maturation, further fragmentation of the elastic
lamina is required for complete arterial dilation and
normalization of arterial shear stress.28,29 This fragmentation
is mediated by metalloproteases (MMPs) and can be blocked
by inhibitors of nitric oxide synthase suggesting that metal-
lloproteinase activation is under the control of endothelial-
derived nitric oxide.30 Inhibitors of metalloprotease activa-
tion or nitric oxide synthesis partially prevented the arterial
dilation and normalization of shear stress.27,30 Using a mouse
carotid-jugular arteriovenous model, Castier et al.31 have
further shown that both the increase in MMP activity and
arterial dilation after fistula formation were completely lost in
mice with homozygous targeted deletion of endothelial
nitric oxide synthase. The study by Castier et al.31 further
demonstrated the importance of reactive oxygen species
and peroxynitrite formation in arterial remodeling. Arterial
dilation and MMP activation was significantly attenuated
after fistula creation in mice with deletion of the p47phox
(p47phox /) subunit of nicotinamide adenine dinucleo-
tide phosphate (reduced form) oxidase. Moreover, peroxy-
nitrite formation (as determined by nitrotyrosine staining)
was increased in the arterial wall after fistula formation and
this was blocked in endothelial nitric oxide synthase (/)
mice and significantly attenuated in p47phox (/) mice.
The increase in MMP activity could be blocked by ebselen, an
inhibitor of reactive oxygen species. Taken together, these
observations suggest that increased shear stress after fistula
formation stimulates both an increase in arterial nitric
oxide and reactive oxygen species that lead to enhanced
formation of peroxynitrite and activation of MMPs required
for arterial remodeling.
Increases in both the mRNA and enzymatic activity of the
gelatinases, MMP-2, and MMP-9 have been detected in the
artery after fistula creation suggesting that these metallopro-
teinases may mediate the observed fragmentation of the
elastic lamina.30–33 However, in one study only increases in
MMP-2 but not MMP-9 were observed, suggesting that the
effect of MMP-2 may predominate.34 MMP-9 is reportedly
more responsive to osillatory rather than unidirectional shear
stress, which might account for a difference in arterial MMP-
2 and MMP-9 activation after fistula formation.35 In addition
to the increase in MMP-2 mRNA, an increase in post-
transcriptional activation of MMP-2 has also been suggested
to occur based on the observation that mRNA for furin
and the furin-activated proprotein convertase MT1-MMP
increase before the increase in MMP-2 activity.32 It is
important to note that activation of MMPs has also been
implicated in the development of neointimal hyperplasia
(NIH), which clearly would be detrimental to arterial
dilation and fistula maturation.36,37 The mechanism whereby
MMP activation promotes expansive remodeling over NIH is
not known.
Interestingly, activation of the toll-like receptor 4 is also
involved in an experimental model of expansive remodel-
ing.37,38 Mice lacking toll-like receptor 4 demonstrated
defective expansive remodeling associated with an increase
in arterial collagen content suggesting that the toll-like
receptor 4 plays a role in collagen turnover required for
arterial remodeling.38 Further investigation is needed to
better understand the mechanism of expansive remodeling
after fistula formation in experimental models and to
determine whether similar events occur after fistula forma-
tion in patients.
In experimental models of expansive remodeling after
fistula formation, the cross-sectional area of the arterial wall
increases following fistula creation, composed of increased
elastin, collagen, and possibly smooth muscle cells.23,27 In
human studies, no measurable increase in wall cross-sectional
area was found in the proximal radial artery at 12 weeks after
fistula formation.19,20 However, after 1 year the radial artery
wall does appear to thicken, presumably in response to the
increased circumferential wall stress caused by arterial
dilation.20 This implies that remodeling of the radial artery
after fistula formation in humans acutely involves lumen
dilation but over time there is vessel wall thickening
presumably associated with cellular proliferation and an
increase in overall matrix formation similar to that seen in
experimental models.
Venous dilation is the clinically more apparent process in
fistula maturation that ultimately determines fistula suit-
ability. Vein dilation occurs rapidly after fistula creation and
continues over several weeks. In a study by Wong et al.,39
average luminal vein diameter increased by 56% 1 day after
surgical creation and further increased to 123% of control at
12 weeks in forearm fistulas that ultimately were successful
for hemodialysis. Similarly, Corpataux et al.18 found that
vein lumen increased by 86% at 1 week and 179% at
12 weeks compared to the contralateral non-operated vein.
The increase in fistula blood flow follows a similar time
course with a rapid increase immediately following surgical
anastomosis followed by a gradual increase to maximal blood
flow within 4–12 weeks thereafter.15,16,18,39,40 Although
variation in the rate of blood flow increase does occur,
typically fistulas attain 40–60% of maximal blood flow within
1 day after surgical anastomosis.15,16,39,40 Near-maximal
blood flow is achieved within 4 weeks in most forearm
fistulas.16,39 These small single-center studies suggest that
most fistulas should be suitable for dialysis within 4 weeks
and failure to attain suitability by this time point is an
indication for further evaluation.4 However, some fistulas
take longer to mature and further investigation is needed to
determine the optimal time to assess fistula maturation.
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Corpataux et al.18 examined the determinants of vein
dilation after fistula formation. Venous pressure increased
immediately after fistula creation but only to a mean pressure
of about 30% of that seen in the immediate upstream artery
(49719/24.576 vs 151714/92.4711 mm Hg in the artery18).
The large pressure drop was attributed to increased resistance
owing to energy loss from turbulent blood flow at the
anastomosis (documented clinically by the palpable thrill
present over the anastomosis).41 The increase in luminal
pressure mediates the rapid early vein dilation. However, the
vein still retained substantial compliance reserve as demons-
trated by preserved systolo-diastolic diameter changes that were
similar to or greater than those seen in the radial
artery despite the lower venous systolo-diastolic pressure pulse.
Despite the early dilation, the increased blood flow was
associated with an increase in vein WSS immediately after
fistula formation. Over the next 12 weeks, calculated shear
stress gradually decreased as vein luminal diameter increased.
This gradual increase in diameter occurred without a further
increase in venous pressure. Hence, it appears that increased
venous pressure accounts for the rapid early increase in vein
diameter but that the subsequent venous dilation is a response
to normalize the flow-induced increase in WSS. The
biochemical mechanism that mediates flow-induced dilation
in veins has not been explored to the same extent as in arteries.
In clinical studies, using currently available techniques
vein wall thickness does not change measurably after fistula
creation. However, the substantial increase in vein diameter
with a fixed wall thickness leads to a marked increase in the
calculated vein wall cross-sectional area.18 This eccentric
venous hypertrophy is likely mediated by the increased
circumferential wall distention or stress that results from
venous dilation and increased luminal pressure. In an
experimental aortocaval fistula model, histological evidence
of venous thickening was observed and characterized by NIH,
smooth muscle cell proliferation and increased extracellular
matrix deposition.42 There was also evidence of histological
injury with early upregulation of mRNA for MCP-1, PAI-1,
and endothelin-1 and later upregulation of mRNA for the
fibrogenic cytokine, transforming growth factor-b. These
changes are similar to those seen in human veins used for
arterial interposition grafts.43 The role of MMPs in venous
remodeling of an arteriovenous fistula has not been reported.
In vein grafts exposed to arterial pressure and flow, both
MMP-2 and MMP-9 have been reported to increase.44,45
However, the temporal change and cell-type-specific localiza-
tion of these MMPs was not consistent between the
studies.44,45 Taken together, these studies demonstrate that
veins respond to increased pressure and shear stress by
activating genetic stress and injury programs leading to
venous wall hypertrophy associated with neointimal and
medial thickening.
PREDICTORS OF MATURATION
Several studies have looked at factors that might predict
fistula maturation. Preoperative vascular mapping has been
shown to improve the rate of fistula placement and overall
surgical success rate.2,46 However, surprisingly neither
preoperative vein nor artery size has been found to be
uniformly reliable as a predictor of successful fistula
maturation into a suitable access.39,47,48 Very small arteries
(e.g. less than 1.6 mm) and veins will likely fail (the exact
cutoff likely depending on surgical experience and expertise)
but above this lower limit preoperative vessel size does not
accurately predict maturation.39 Preoperative measurement
of venous compliance was a predictor of subsequent fistula
maturation in one recent study49 but only a weak predictor of
fistula maturation in two earlier studies.40,50 On the other
hand, several studies have shown that postoperative flow rate
measured by Doppler ultrasound in a forearm fistula is a
moderately good predictor of fistula maturation.39,51,52 These
studies have reported using a cutoff between 400 and 500 ml/
min at 2–8 weeks as a predictor of fistula maturation. A
clinical examination of the fistula may be as accurate as
Doppler flow measurements.4,52 However, the criteria for
making a clinical determination by physical examination
have not been rigorously established and tested. Collectively,
these studies suggest that the functional ability of the artery
and vein to dilate and achieve a rapid increase in blood flow
after surgery may be the most important determinant of
fistula maturation. Consistent with this, a study by Malovrh50
demonstrated that preoperative measurement of arterial
dilation in response to reactive hyperemia (generated after
release of a fist clenched for 2 min) could predict subsequent
forearm fistula maturation. A resistive index of less than 0.7
at reactive hyperemia had 95% sensitivity, 61% specificity,
and 87% positive predictive value for predicting forearm
fistula maturation. This observation was not confirmed in a
more recent study, but there appear to be differences in the
measurement techniques (use of velocity flow rate vs volume
flow rate to calculate resistive index) that might account for
the difference.48 Other factors that have been reported to
influence fistula maturation include surgical experience,
gender, and evidence of extensive vascular disease.6,53,54 The
observation that women have poorer fistula maturation than
men has been frequently reported and assumed to be due to
smaller vessel size. However, two recent studies found no
gender difference in preoperative arterial or venous dia-
meter.53,55 Despite equivalent preoperative vessel size, in one
study maturation was poorer in women53 but in the other
study maturation rates were equivalent.55 More work is
needed on this interesting observation.
ANATOMICAL CORRELATES OF IMPAIRED MATURATION
When evaluated by angiography, most insufficient fistulas
have one or more anatomic lesions that underlie the impaired
maturation.7,56–58 Correcting the lesions has been shown
to improve the overall rate of fistula maturation implying
that the lesions are functionally important.7,58 The most
common finding is venous stenosis occurring in 65–100%
of angiographically evaluated failing fistulas.7,56–58 More
than half of the stenoses occur in the vein immediately
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downstream of the anastomosis (juxta-anastomotic stenosis)
and frequently involve the anastomosis itself. Stenoses also
occur further downstream in the proximal vein as well as less
frequently in the central vein or feeding artery. The presence
of accessory veins has also been reported to be an important,
potentially remediable contributor to poor fistula maturation
in some studies.7 The primary problem is not the accessory
vein but the impaired arterial and/or venous dilation that
limits overall fistula flow. Shunting of blood into accessory
veins prevents sufficient flow developing in the main cephalic
vein to permit fistula dilation and maturation. Finally, in one
prospective controlled study, 35% of fistulas that did not
mature had no detectable lesion by angiography suggesting
that failure of arterial and/or venous dilation rather than
stenosis was the predominant cause of failure in this
subgroup.57 All of the single-center studies published to date
have limitations.59 Stenotic lesions may have been missed
owing to technical limitations in the prospective study by
Tordoir et al.57 whereas referral bias may have increased the
prevalence of stenosis and accessory veins in the studies by
Beathard et al.7 and Turmel-Rodrigues et al.58 Moreover,
center-specific variations in the intensity of preoperative
vascular mapping or choice of vessels may influence the
frequency of seeing impaired dilation as a cause of impaired
maturation. Collectively, these studies imply that venous
stenosis, impaired arterial and venous dilation, and accessory
veins account for most cases of impaired fistula maturation
but the exact frequency of each cause remains uncertain.
PATHOGENESIS OF IMPAIRED FISTULA MATURATION
Arterial and venous dilation are critical for fistula maturation
(Figure 1). Impaired dilation may be due to both structural
and functional factors. An increase in radial artery intima–-
media thickeness has been reported to correlate with
decreased fistula maturation.60 Structurally, increased arterial
wall stiffness and increased intima–media thickness have been
found in patients with end-stage renal disease (ESRD).61–64
Pathologic analysis of muscular arteries and cephalic
vein from patients with ESRD has demonstrated neointimal
thickening.65–67 Overlying endothelial cells look abnormal
with focal areas of denuded endothelium exposing under-
lying basement membrane and intima.67 Smooth muscle
cells in the neointima are disordered and ultrastructurally
appear to be dedifferentiated to a synthetic (rather than
contractile) phenotype.66,68 In addition, there is an increase
in extracellular matrix material composed of collagen and
mucopolysaccarides.65–68 Vascular wall calcification is fre-
quently seen50,65–68 and likely contributes to increased arterial
stiffness.69 These changes have been confirmed in an
experimental model of uremia where much of the wall
thickening and stiffness was reportedly due to increased
deposition of extracellular matrix material including collagen
but not elastin.70,71 The exact pathogenesis of the arterio-
sclerosis and vascular calcification is not certain. In addition
to underlying hypertension, diabetes, and age, chronic
kidney disease itself is an independent risk factor for
arteriosclerosis and vascular calcification.72 Some potential
mediators include an enhanced systemic inflammatory
mileau, increased oxidative stress, disordered phosphorus
and calcium metabolism, circulating inhibitors of nitric oxide
synthase (e.g. asymmetric dimethylarginine), and others that
are the subject of recent reviews.73–77
Endothelial dysfunction occurs in ESRD leading to
impaired endothelium-mediated release of nitric oxide
and arterial dilation in response to increased flow rate.13,78
This defect can be transiently reversed by dialysis suggesting
a role for circulating inhibitors of nitric oxide synthase such
as asymmetric dimethylarginine.78,79 However, provision of
excess substrate, L-arginine for nitric oxide synthase does not
reliably reverse the defect in endothelial function implying
that factors other than competitive nitric oxide synthase
inhibitors (such as asymmetric dimethylarginine) may be
involved.79,80 The defect in endothelial function and nitric
oxide release may also impair the release of metalloprotein-
ases necessary for elastin fragmentation and progressive
arterial dilation and remodeling in response to increased
shear stress.27,30
NIH leading to a focal or diffuse area of stenosis is the
other predominant cause of impaired fistula maturation. The
presence of venous NIH at the juxta-anastomotic region
suggests that hemodynamic and rheological forces on the
vein may play an important role in stimulating NIH. Studies
of atherosclerosis and arterial bypass grafts have correlated
the development of NIH with regions of low or oscillating
WSS.81 In addition, excessively high WSS can also damage
endothelial cells and activate platelets leading to NIH.82
In vitro modeling of WSS in an end to side fistula model
has demonstrated the presence of a low mean WSS with
a highly oscillatory pattern at the arterial floor opposite
the anastomotic os and at the ‘heel’ of the anastomosis.41
High mean WSS with an oscillatory pattern occurs at the
anastomotic ‘toe’ and in the outer wall of the vein within
1 cm of the anastomosis.41 However, the abnormal shear
stress and oscillatory pattern rapidly subsides beyond 1 cm of
the anastomosis and may not explain the areas of venous
juxta-anastomotic stenosis seen further downstream on
angiography. Further in vivo studies measuring regional
WSS and correlating that with the development of stenosis
over time in developing fistulas is needed to better determine
the role of rheological and hemodynamic factors in fistula
maturation and stenosis.15
Juxta-anastomotic stenoses in forearm fistulas appear to
arise in the surgical hinge region where the vein is mobilized
and moved into contact with the artery at the time of fistula
creation. This segment of vein is subject to surgical trauma
with possible desiccation, crush injury, kinking, spasm,
or other insults during fistula creation.3 These stresses may
further damage the endothelium of an already fragile vein,
exposing the underlying extracellular matrix and inciting
an injury response including proinflammatory cytokine
release that initiates NIH. The care and expertise required
to anastomose these small vessels is evident.3 Strategies that
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improve preoperative vessel structure and function and
reduce vascular injury at the time of surgical creation may
be critical steps towards improving maturation.
Finally, injuries that promote NIH in the proximal or
central vein are presumed to be due to prior venous
catheterization, thrombophlebitis, or areas of venous branch-
ing. The association between central venous stenosis and
prior subclavian venous catheters is established.83 However,
the specific factors leading to stenoses in the proximal vein
have been less well studied.
POSSIBLE FUTURE APPROACHES TO IMPROVE FISTULA
MATURATION
What can be done to improve fistula maturation? Preserva-
tion of veins, preoperative vascular mapping, and an
experienced surgeon are important factors that are currently
recommended. Antiplatelet agents are not routinely used
following fistula surgery but have been reported to prevent
early post-operative thrombosis in a few small trials. A large
multicenter randomized placebo-controlled trial is currently
underway to determine whether 6 weeks of clopidogrel will
prevent early thrombosis and improve fistula maturation.8
Earlier identification and treatment of a failing fistula is
needed to shorten the time from fistula creation to usability
and thereby help to curtail the high rate of central venous
catheter use for hemodialysis.4 However, cross-center
validated criteria that allow early and reliable identification
of the failing fistula must be established. The most common
intervention at this time, particularly for stenosis is
angioplasty but the results are often not durable and require
repeated interventions to maintain patency.58 Hence, better
strategies are needed to deal with the etiologies of impaired
fistula maturation when they are identified.
Therapeutic strategies that target NIH particularly at the
juxta-anastomotic region need to be studied. In experi-
mental models, allogeneic endothelial cells impregnated
into a gelfoam matrix and applied to the periadventitial
surface over the anastomotic region of a newly created fistula
inhibited NIH.84 A clinical trial of this product known as
VascuGel (Pervasis Therapeutics, Cambridge, MA, USA) is
currently being planned. Infusion or cytokine mobilization
of circulating endogenous endothelial progenitor cells to
populate the damaged endothelial lining after fistula creation
may be another novel strategy to limit NIH.85,86 However, a
recent trial using anti-CD34 antibody-coated grafts to recruit
endothelial progenitor cells to coat the lumen surface of an
arteriovenous graft resulted in increased NIH.87 Hence, much
more preclinical investigation is needed to better understand
how to use this novel strategy.
A large number of cytokines and growth factors such as
PDGF, transforming growth factor-b, and interleukin-1b are
known to play a role in the pathogenesis of NIH. Inhibitors
of some of these cytokines and their signaling pathways (e.g.
imatinib) are approved for therapeutic use or are in clinical
trials for other applications and need to be tested for their
ability to prevent NIH in fistulas.88,89 Pharmacological agents
such as sirolimus, paclitaxel, or dipyridamole, which have
been shown to inhibit NIH in other situations, may also be
useful to test in native fistulas.69,90,91 Local delivery of these
agents either from the luminal side of the fistula possibly in
the form of a drug-eluting stent or from the adventitial
surface are strategies that may allow higher local drug
concentrations with lower systemic toxicity and need to be
explored.92 Local gene therapy at the time of surgery to
deliver molecules that might prevent subsequent NIH (e.g.,
nitric oxide synthase or bARKct) or facilitate more favorable
remodeling (e.g., C-natriuretic peptide) may also be a useful
strategy to pursue.93–95 However, the proper delivery plat-
form and safety issues will need to be addressed before taking
this strategy to the clinic. A recent trial using edifoligide, a
double-stranded oligonucleotide decoy for E2F, demon-
strated the feasibility of one type of genetic approach.
However, it was ultimately unsuccessful at preventing
stenosis in vein bypass grafts.96 Finally, pharmacological
strategies that optimize vessels for surgical anastomosis and
modulate vascular remodeling may also reduce intraoperative
damage and subsequent NIH. Recent evidence from experi-
mental studies suggests that application of elastase to the
adventitial surface of balloon-injured arteries and vein
grafts promotes outward remodeling and can prevent NIH
after injury.97,98 Prot-101 (Proteon Therapeutics, Kansas
City, MO, USA) is an elastase that promotes vasodilation
and prevents vasospasm. It is currently in preclinical trials
as a possible agent to prevent NIH formation after
fistula creation.
Therapy to prevent vascular damage and dysfunction in
people with chronic kidney disease before they need a fistula
is a long-term goal that would improve fistula maturation.
Surprisingly, it is unknown whether currently available
therapeutic interventions such as exercise, angiontensin-
converting enzyme inhibitors, or statins that improve
endothelial function in patients with cardiovascular disease
and normal renal function, improve endothelial function and
fistula maturation in ESRD. The recent Deutsche Diabetes
Dialyse Studie trial that failed to show a survival benefit of
atorvastatin in hemodialysis patients suggests that addition of
statins to people already on dialysis may not improve
endothelial function but this has not been tested.99 Further
study is also needed to identify the dialyzable factor(s) that
mediate the endothelial dysfunction in chronic kidney disease
and whether their removal or control would improve fistula
maturation. Therapies that could ameliorate the increased
oxidative stress and activated inflammatory pathways are
being investigated and if successful would likely improve
fistula maturation.74,100 Direct efforts to improve vascular
compliance might also be a future target for therapeutic
intervention. Advanced glycation end products likely con-
tribute to the reduced vascular compliance in patients with
ESRD. One lead compound ALT-711 (Alagebrium, Alteon,
NJ, USA) has been reported to improve vascular compliance
and is currently in clinical trials for diastolic heart failure.101
Finally, reducing the burden of vascular calcification would
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improve vascular compliance and fistula maturation. In
addition to controlling the serum calcium and phosphorus,
future strategies such as use of bone morphogenic factor 7
may be useful to control vascular calcification.102,103
CONCLUSION
Fistula maturation requires a compliant and responsive
vasculature capable of dilating in response to the increased
velocity of blood flowing into the newly created low-
resistance circuit. Successful maturation to a high volume
flow circuit capable of sustaining hemodialysis typically
occurs within the first few weeks after creation. Failure to
achieve maturation within 4–8 weeks should prompt a search
for reversible etiologies; however, an accepted definition of
maturation, particularly for patients not yet on dialysis
remains elusive. The most commonly identified etiology is
NIH typically occurring in the juxta-anastomotic vein.
However, failed maturation has also been reported secondary
to impaired arterial and venous dilation and accessory veins.
The exact frequency of each of these etiologies is unclear.
Understanding the etiologies of impaired fistula maturation
will focus future studies of targeted interventions to improve
the rate of fistula maturation and increase the number of
dialysis patients with a functioning autogenous fistula.
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